NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of “Moderate Buy” from Analysts

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has been given an average recommendation of “Moderate Buy” by the fourteen research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $49.4167.

A number of equities research analysts have weighed in on the company. BMO Capital Markets began coverage on NewAmsterdam Pharma in a report on Monday. They issued an “outperform” rating and a $58.00 target price on the stock. Royal Bank Of Canada boosted their price target on NewAmsterdam Pharma from $47.00 to $51.00 and gave the stock an “outperform” rating in a report on Tuesday, June 30th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a research note on Monday.

NewAmsterdam Pharma Trading Down 3.6%

Shares of NewAmsterdam Pharma stock opened at $30.55 on Friday. The company has a 50 day moving average of $32.92 and a 200-day moving average of $32.89. NewAmsterdam Pharma has a 1-year low of $21.14 and a 1-year high of $42.21. The company has a market cap of $3.57 billion, a PE ratio of -17.07 and a beta of 0.08.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The firm had revenue of $3.04 million during the quarter. Research analysts forecast that NewAmsterdam Pharma will post -1.78 earnings per share for the current year.

Insider Activity

In related news, CAO Louise Frederika Kooij sold 40,000 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $30.20, for a total transaction of $1,208,000.00. Following the completion of the transaction, the chief accounting officer directly owned 24,353 shares in the company, valued at $735,460.60. This represents a 62.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 12.74% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wells Fargo & Company MN lifted its stake in shares of NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after acquiring an additional 300 shares during the last quarter. Geode Capital Management LLC grew its position in NewAmsterdam Pharma by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock worth $3,590,000 after acquiring an additional 437 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in NewAmsterdam Pharma by 5.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after acquiring an additional 544 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in NewAmsterdam Pharma by 4,425.0% in the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after purchasing an additional 708 shares in the last quarter. Finally, AlphaCentric Advisors LLC increased its holdings in NewAmsterdam Pharma by 6.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 14,656 shares of the company’s stock worth $469,000 after purchasing an additional 925 shares in the last quarter. Institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.